Incyte Corporation’s efforts to maintain Jakafi’s (ruxolitinib) place in the market before its exclusivity runs out hit a snag with the announcement that it stopped a combination trial of the drug in myelofibrosis because the study would not likely hit its primary endpoint.
Incyte’s Jakafi Flunks In Phase III Myelofibrosis Study As Loss Of Exclusivity Nears
The company said it would discontinue the Phase III LIMBER-304 trial in patients who had inadequate response to Jakafi when an analysis indicated the study would not reach its primary endpoint.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from R&D
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.